(0.19%) 5 532.25 points
(0.14%) 39 526 points
(0.21%) 19 969 points
(0.75%) $82.15
(-0.96%) $2.58
(-0.20%) $2 335.00
(-0.20%) $29.50
(0.47%) $1 006.60
(-0.50%) $0.929
(-0.62%) $10.61
(-0.25%) $0.789
(1.63%) $87.12
0.00% £ 3.15
Live Chart Being Loaded With Signals
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer...
Stats | |
---|---|
Volumen de hoy | 154 542 |
Volumen promedio | 1.86M |
Capitalización de mercado | 4.17M |
EPS | £-0.00980 ( Q4 | 2023-12-31 ) |
Próxima fecha de ganancias | ( £0 ) 2024-08-21 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E |
-1.570 (Sector) 0 (Industry) 0 |
ATR14 | £0.0990 (3.14%) |
ValiRx PLC Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
ValiRx PLC Finanzas
Annual | 2023 |
Ingresos: | £9 600.00 |
Beneficio Bruto: | £-246 043 (-2 562.95 %) |
EPS: | £-0.0201 |
FY | 2023 |
Ingresos: | £9 600.00 |
Beneficio Bruto: | £-246 043 (-2 562.95 %) |
EPS: | £-0.0201 |
FY | 2022 |
Ingresos: | £0 |
Beneficio Bruto: | £-224 268 (0.00 %) |
EPS: | £-0.0311 |
FY | 2021 |
Ingresos: | £0.00 |
Beneficio Bruto: | £0.00 (0.00 %) |
EPS: | £-0.0401 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
ValiRx PLC
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico